Skip to content
Home/Companies/Biotech/VectivBio

VectivBio

Biotech·Switzerland·Exited 2023·Held 6yr
Entry
2017
Hold
6yr
Exit
2023

Who owns VectivBio?

VectivBio is a Swiss Biotech company, now owned by Ironwood Pharmaceuticals, which acquired it in 2023 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VIII · 2015 · Life Sciences VC

Key facts

HQSwitzerland
SectorBiotech
Exit Type
Trade Sale
Buyer
Ironwood Pharmaceuticals
Exit Year
2023

More from Sofinnova Capital VIII

Other portfolio companies in the same fund.

Breath Therapeutics
Exited 2019
BiotechGermany· 2016
to Zambon
Corvidia Therapeutics
Exited 2020
BiotechUS· 2016
to Novo Nordisk
Delinia
Exited 2017
BiotechUK· 2016
to Celgene
ENYO Pharma
ENYO Pharma
Active
BiotechFrance· 2016
ReCor Medical
Exited 2018
MedTechUS· 2016
to Otsuka Holdings
BiovelocITA
Active
BiotechItaly· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns VectivBio?

VectivBio is now owned by Ironwood Pharmaceuticals, which acquired it in 2023 from Sofinnova Partners.

When did Ironwood Pharmaceuticals acquire VectivBio?

Ironwood Pharmaceuticals acquired VectivBio in 2023, buying from Sofinnova Partners.

Who did VectivBio sell to?

Sofinnova Partners sold VectivBio to Ironwood Pharmaceuticals in 2023 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue